10 2 8 30 9 55 SOP 2 P-044 P-045 2 P-046 :Frasier 1 1 1 1 1 1 2 2 1 1 2 P-047 GH 1 1 2 2 2 2 2 1 2 P-048 Bartter 1 1 1 1 2 1 2 P-049 SD IGF-1 GHD P-050-2SD GHD 1 2 2 2 1 2 P-051 GHD 1,2 1 1 1 1 1 2 2 3 1 1 2 3 P-052 1 2 2 2 2 2 1 2 25
P-053 1 2 1 2 P-054 GHD GH SGA P-055 SGA 1 1 1 1 1 1 2 2 1 2 P-056 SGA GH P-057 SGA 1 1 1 2 2 2 2 2 1 1 1 2 P-058 3 1,2 1,3 1,4 1,5 Trace The Turner study group 1 2 3 4 5 P-059 1 2 3 2 1 2 3 P-060 MRI 1 1 1 1 2 3 4 1 2 3 4 P-061 Silver-Russell H19-DMR 1 1 2 3 3 1 1 2 3 P-062 H19-DMR Silver-Russell 1 1 2 1 2 1 2 P-063 1 1 1 2 3 1 1 2 2 3 26
P-064 Silver-Russell syndrome 1 1 2 2 1 1 2 P-065 88 7 1,2 1,2 1 3 4 5 6 6 2 1 1 2 3 4 5 6 P-066 Russell-Silver 13 P-067 1 1 1 1 2 1 1 2 P-068 2 P-069 HESX P-070 Bartter Giteleman 1 1 1 2 3 1 2 3 P-071 P-072 P-073 New Bioassay System for GH Determination 1 1 1 1 1 2 1 1 2 P-074 1 1 3 4 5 2 2 2 2 1 2 3 4 5 P-075 BMI 1 2 1 1 1 1 2 27
P-076 DDAVP 1 1,2 1 1 1 1 1 1 2 P-077 AVP 1 1 1 1 2 2 1 1 2 P-078 AVP AQP2 1 1 1 1 1 2 2 2 1 1 2 P-079 V2 P-080 V2R 2 1 1 1 1 1 1 2 3 1 2 3 P-081 septo-optic dysplasia 1 P-082 septo-optic dysplasia 1 1 2 2 1 2 P-083 Na 18q- 1 P-084 PRL Cushing 1 3.0 MRI 1 1 1 1 1 1 1 2 3 1 2 3 P-085 1 1 2 3 1 2 3 P-086 3 1 1 3 2 1 2 3 28
P-087 1 1 2 2 2 2 2 3 4 5 1 2 3 4 5 P-088 2 P-089 1 1 1 1 1 1 1 2 3 1 1 2 3 P-090 14 catch-up growth 1 1 1 2 3 3 3 1 2 3 P-091 P-092 Pallister-Hall 1 1 1 2 2 2 2 2 1 1 1 2 P-093 growth without GH 2 GH 1 1 2 3 4 5 1 2 3 4 5 P-094 1 2 2 2 3 3 4 5 1 2 3 4 5 P-095 6 1 2 2 2 2 2 3 4 1 2 3 4 P-096 2 RS Na 29
P-097 Nesfatin-1 P-098 SF-36 QOL 6 1 2 3 4 5 6 1 2 3 4 5 6 P-099 Tachykinin 3 1 2 1 1 3 1 1 2 3 P-100 -osteosclerotic variant of osteogenesis imperfecta- P-101 1 1 2 1 2 P-102 HDR hypoparathyroidism, deafness, and renal dysplasia 1 1 1 1 1 2 3 1 2 3 P-103 1 1,2 2,3 2,4 2 2,5 2 6 2 1 2 3 4 5 6 P-104 1b 1 2 3 1 1 2 1 2 3 P-105 Ia 1 1 1 1 1 1 2 1 2 P-106 1 2 2 2 2 2 1 2 P-107 GCMB 1 1 1 2 1 1 1 2 30
P-108 1 1 2 1 3 1 2 3 P-109 D 1 1 1 1 1 2 2 1 2 P-110 D 2 P-111 1 2 1 2 2 2 1 1 2 P-112 TRPM6 P-113 TCIRG1 1 1 1 1 1 1 1 1 2 2 1 2 P-114 Acampomelic campomelic dysplasia 1 1 1 1 2 1 1 3 1 1 1 2 3 P-115 Fanconi 1 1 1 1 1 1 1 2 2 3 3 1 2 3 P-116 McCune-Albright 2 P-117 P-118 1 2 2 2 2 2 1 2 31
P-119 1 1 1 1 1 2 1 1 1 1 2 P-120 infantile myofi bromatosis marker 1 2 3 4 5 1 2 3 4 5 P-121 IGF-I 1 1 Mejia Wilson 2 Sun Hui 2 Wu Yinjgie 2 Rosen Clifford J 3 Clemmons David 4 Yakar Shoshana 2 1 Division of Endocrinology, Diabetes and Bone disease, Mount Sinai School of Medicine 2 Maine Medical Center Research Institute 3 Division of Endocrinology, University of North Carolina 4 10 00 10 40 2 OR-04 OR-05 OR-06 OR-07 1 2 1 2 AVP OTX2 1,2 2 3 3 4 5 5 1 6 2 1 2 3 4 5 6 GnRH GnRH 1,2 1 2 2 1 2 32
10 40 11 20 3 OR-08 OR-09 OR-10 OR-11 Kallmann FGFR1 acid box 1 2 2 3 1 1 2 3 1 1 1 2 3 1 2 3 MAMLD1 1 1 1 2 1 3 4 1 1 1 2 3 4 11 20 12 00 4 OR-12 OR-13 D 1,2 1 D 2 1,2 1 1 1,2 1 1 1 2 1 2 33
OR-14 OR-15 21 14 00 14 30 5 1 OR-16 OR-17 OR-18 TRH T4 T3 1 1 1 2 2 1 1 2 ft4 1 2 3 4 5 5 1 2 3 4 5 14 30 15 00 6 2 OR-19 TSH 1 1 2 1,3 1,4 1,5 1,6 1 1 2 1 1 2 3 4 5 6 34
OR-20 OR-21 MMI 1 1 1 1 1 1 2 1 3 4 1 1 1 2 3 4 1,2,3 2 2,3 2 2 2 2 3 3 3 3 3 3 3 3 4 5 1 2 3 4 5 15:00 16:00 16:10 16:40 30 16:40 17:40 1 Disorders of Sex Development(DSD): the Challenge of Management Ieuan A. Hughes, MD, FRCP Head of Department, University of Cambridge School of Clinical Medicine, Department of Paediatrics, Addenbrooks Hospital, Cambridge, UK. 35
17:45 19:10 1 Sy1-1 Sy1-2 Sy1-3 Sy1-4 1,2 1 2 36